Upstate Active Clinical Trials

Study Title:

Alliance A031203: Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma

What is the purpose of the study?

This randomized phase II trial studies how well cabozantinib-s-malate works compared to sunitinib malate in treating patients with previously untreated locally advanced or metastatic kidney cancer. Cabozantinib-s-malate and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether cabozantinib-s-malate or sunitinib malate is more effective in treating patients with kidney cancer.

Upstate Institutional Review Board (IRB) Number:

554082

Study Phase:

II

Patient Age Group:

Adults

Principal Investigator:

Sam Benjamin, MD

ClinicalTrials.Gov ID:

NCT01835158

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Wendy S Barry
Phone: 315-464-8271
Email: barryw@upstate.edu

Return to Previous Page || Search Again